{"id":"NCT01039688","sponsor":"Pfizer","briefTitle":"Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX","officialTitle":"Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2013-03","completion":"2013-03","firstPosted":"2009-12-25","resultsPosted":"2018-04-06","lastUpdate":"2018-04-06"},"enrollment":956,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Arthritis, Rheumatoid"],"interventions":[{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"CP-690,550","otherNames":[]},{"type":"DRUG","name":"Disease-modifying antirheumatic drug","otherNames":["DMARD, MTX"]}],"arms":[{"label":"5 mg BID CP-690,550","type":"EXPERIMENTAL"},{"label":"10 mg BID CP-690,550","type":"EXPERIMENTAL"},{"label":"methotrexate","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to compare the effectiveness of the experimental drug, CP-690,550, to methotrexate in preventing joint damage and improving symptoms of rheumatoid arthritis. This study will also compare the safety of CP-690,550 with methotrexate.","primaryOutcome":{"measure":"Modified Total Sharp Score (mTSS) at Month 6","timeFrame":"Month 6","effectByArm":[{"arm":"CP-690,550 5 mg BID","deltaMin":20.5,"sd":40.58},{"arm":"CP-690,550 10 mg BID","deltaMin":18.85,"sd":39.21},{"arm":"MTX 10, 15, or 20 mg, Weekly","deltaMin":17.54,"sd":29.96}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":176,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","Chile","Colombia","Costa Rica","Czechia","Dominican Republic","Germany","Hungary","India","Malaysia","Mexico","New Zealand","Peru","Philippines","Poland","Puerto Rico","Russia","Slovakia","South Korea","Spain","Sweden","Taiwan","Thailand","Ukraine"]},"refs":{"pmids":["39192350","38958913","38883150","37773189","37453736","36931693","36814062","36601090","36600185","36526796","35577477","34870800","34057820","33127856","33059710","33057725","32816215","30177460","29761420","29696833","28143815","27493790","27175296","25047021","24941177"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921069&StudyName=Comparing%20The%20Effectiveness%20And%20Safety%20Of%202%20Doses%20Of%20An%20Experimental%20Drug%2C%20CP-690%2C550%2C%20To%20Methotrexate%20%28MTX%29%20In%20Patients%20With%20"]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":373},"commonTop":["Nausea","Upper respiratory tract infection","Nasopharyngitis","Headache","Hypertension"]}}